 SOUTH SAN FRANCISCO, Calif., March 05, 2021 GLOBE NEWSWIRE -- Assembly Biosciences, Inc. Nasdaq: ASMB, a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus HBV, today announced grants of stock options to three new employees to purchase an aggregate of 26,000 shares of the Companys common stock with an exercise price of 5.05 per share, the closing price of Assembly Bios common stock on March 1, 2021. The stock options were granted as material inducements to the new employees to accept the Companys offers of employment. 